BOSTON and JERUSALEM, March 04, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate in the H.C. Wainwright Global Life Sciences Conference.

‒ EB612 When Added to Standard of Care Led to a Statistically Significant Decrease in  Supplemental Calcium Usage – ‒ Oral Human Parathyroid Hormone (1-34) Has the Potential to Have a Major Impact on Compliance, Adherence, Therapeutic Impact and Quality of Life for Patients – BOSTON and JERUSALEM,

‒ Program Leverages Entera’s Platform for Potential Development of Oral GLP-2 Analogs for Gastrointestinal and Other Indications ‒ ‒ GLP-2 Analogs Currently Administered Via Daily Injection to Treat Short Bowel Syndrome ‒ BOSTON, Mass. & JERUSALEM, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board

EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21 BOSTON and JERUSALEM, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

BOSTON and JERUSALEM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Spiros Jamas, Sc.D. to the role of Chief Executive Officer and a member of

‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density ( BMD ) Data Reported in Phase 2 EB613 Clinical Trial ‒ ‒ Company Expect s to Report Bio m arker

BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on November 19, 2020, before the U.S.

‒ Company Expect s to Report Interim 3 Month Bio m arker Data for All Enrolled Patients in Q1:21   with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒ ‒ Results Expected Are Expected to Inform the Design of Potential Global Phase 3 Clinical Trial ‒ BOSTON and JERUSALEM, Israel, Nov.

BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C.